These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Acceptability of pre-exposure HIV prophylaxis clinical trial among MSM in Shenyang city].
    Author: Mao X, Yu H, Hu QH, Zhang J, Chu ZX, Wang YN, Geng WQ, Jiang YJ, Xu JJ.
    Journal: Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Aug 10; 38(8):1083-1087. PubMed ID: 28847059.
    Abstract:
    Objective: To investigate the acceptability and related factors of an "on-demand" pre-exposure prophylaxis (PrEP) to prevent HIV transmission among MSM in Shenyang. Methods: MSM recruited by non-probability sampling method and questionnaire survey conducted by investigators to collect information on social and behavioral characteristics, awareness of PrEP, Truvada and the acceptability of two different PrEP-based trials. Multivariate logistic regression was employed for statistical analysis. Results: Among the 292 respondents, 34.2% had heard of PrEP and 58.2% (170/292) reported were interested in participating a PrEP trial- "on-demand" use or 48.3% (141/292) interested on "daily" use (χ(2)=5.785, P=0.02). Factors independently associated with those "on-demand" would include: having more than 2 male sexual partners during the past 6 month (aOR=1.7, 95%CI: 1.1-2.7), concerning on the positive effect of PrEP (vs. side effects) (aOR=6.4, 95%CI:2.2-18.9), having an HIV-infected sexual partners (aOR=8.1, 95%CI: 1.0-63.3) and self-reported high risk for HIV (aOR=2.6, 95%CI: 1.2-6.0). The last two factors were only associated with the "on-demand" group. Conclusions: "On-demand" PrEP (as opposed to daily) seemed a more feasible prevention strategy on HIV and particularly in those having high risk behavior of HIV. For those who could not follow the daily medication or having HIV risk perception, "On-demand" basis PrEP trial should be recommended for them to follow. 目的： 探讨沈阳市MSM对事件驱动型（在性行为的前后特定时点）暴露前预防性用药（PrEP）预防HIV感染的接受意愿及其相关因素。 方法： 采用非概率抽样方法招募MSM研究对象，通过访谈式问卷调查获取社会背景学和性行为特征信息、PrEP知晓度、对特鲁瓦达（Truvada）不同服药方式的接受意愿，采用多因素logistic回归分析不同服药方式的相关因素。 结果： 292名MSM参加调查，PrEP知晓率为34.2%，接受事件驱动型服药方案的58.2%（170/292）高于接受日服型（每日定时）服药方案的48.3%（141/292）（χ(2)=5.785，P=0.02）。半年内男性性伴数>2人（aOR=1.7，95%CI：1.1~2.7）、关心药物有效性（aOR=6.4，95%CI：2.2~18.9）是接受两种服药方式共有的相关因素。存在HIV阳性性伴（aOR=8.1，95%CI：1.0~63.3）、自评HIV中高感染风险（aOR=2.6，95%CI：1.2~6.0）是接受事件驱动型服药方案独有的相关因素。 结论： 事件驱动型服药方案相比于日服型更易被MSM群体接受。对无法坚持每日服药、自身具有HIV危险感知意识的MSM建议推荐事件驱动型方案。.
    [Abstract] [Full Text] [Related] [New Search]